用检查点抑制剂治疗的罕见癌症患者的第一周期毒性和生存率
Megan Othus1,2, Sandip P Patel3, Young Kwang Chae4
1SWOG Cancer Research Network Statistical Center, Seattle, WA 98109, United States.
Journal of the National Cancer Institute
|November 20, 2024
概括
检查点抑制剂的免疫相关不良事件 (irAEs) 对罕见癌症的存活率产生影响. 轻度IRAE (1-2级) 与更长的生存时间相关,而严重IRAE (3-4级) 与更短的生存时间相关.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 检查点抑制剂治疗是许多癌症的关键治疗方法.
- 与免疫相关的不良事件 (irAEs) 是这些疗法的常见副作用.
- 之前对irAEs和结果的研究主要集中在常见的瘤类型上.
研究的目的:
- 调查与罕见癌症患者的irAEs和生存结果之间的关联.
- 评估irAE严重程度对整体生存时间 (OS) 和无进展生存时间 (PFS) 的影响.
主要方法:
- 来自联邦资助的篮子试验 (NCT02834013) 的数据分析,包括684名患有罕见癌症的患者.
- 治疗涉及尼沃卢马布和伊皮利穆马布在1000多个地点.
- 使用具有里程碑意义的考克斯回归模型来评估第一周期IRAE与生存结果之间的关联.
主要成果:
- 第一个周期的1-2级IRAE与没有IRAE相比,与显著更长的OS (HR=0.61) 相关.
- 3-4级的IREE与较短的OS相关 (HR=1.41).
- 对于PFS观察到类似但不那么明显的关联;1-2级皮肤毒性显示改善了OS.
结论:
- 在检查点抑制剂治疗的第一个周期中,与免疫相关的不良事件的程度是罕见瘤患者生存的重要预测指标.
- 这一发现凸显了在这种患者群体中监测和管理IRE的重要性.
相关概念视频
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


